SCHEMBL144012

SCHEMBL144012

CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)C=C[C@]4(C)[C@H]3CC[C@@]21C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 6/20 0.62
NR3C1 P04150 6/20 0.62
CYP3A4 P08684 5/20 0.62
DRD1 P21728 1/20 0.62
OPRK1 P41145 1/20 0.62
PDE3A Q14432 1/20 0.62
ADORA3 P0DMS8 2/20 0.59
NR1I2 O75469 2/20 0.59
MLNR O43193 1/20 0.59
HTR2C P28335 1/20 0.59
AR P10275 4/20 0.53
CHRM1 P11229 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 2/20 0.46
CHRM2 P08172 2/20 0.46
MAPK1 P28482 2/20 0.46
HIF1A Q16665 2/20 0.46
THRB P10828 1/20 0.46
TBXA2R P21731 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13518370 0.88 PGR (0.53) PGRNR3C1CYP3A4DRD1OPRK1
SCHEMBL7196456 0.88 PGR (0.65) PGRNR3C1CYP3A4DRD1OPRK1
Delmadinone Acetate SCHEMBL146081 0.83 NR3C1 (0.68) PGRNR3C1CYP3A4DRD1OPRK1
Delmadinone Acetate SCHEMBL146080 0.83 NR3C1 (0.68) PGRNR3C1CYP3A4DRD1OPRK1
Chlormadinone SCHEMBL13358512 0.79 PGR (0.78) PGRNR3C1CYP3A4DRD1OPRK1
Chlormadinone SCHEMBL37291 0.79 PGR (0.78) PGRNR3C1CYP3A4DRD1OPRK1
SCHEMBL8859708 0.79 CYP19A1 (0.60) PGRNR3C1ADORA3NR1I2MLNR
SCHEMBL11798369 0.79 MEN1 (0.70) PGRNR3C1CYP3A4DRD1OPRK1
SCHEMBL13558387 0.79 MEN1 (0.70) PGRNR3C1CYP3A4DRD1OPRK1
SCHEMBL8974618 0.79 MEN1 (0.70) PGRNR3C1CYP3A4DRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 511 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4525938-B1 RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS BAYER AG (DE) 2026-03-11 EP claimed
WO-2023039125-A1 ADENOSINE RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF CANCER TEON THERAPEUTICS, INC. (US) 2023-03-16 WO claimed
EP-3400050-B1 DRUG RELEASE DEVICE AND USE JUROX PTY LTD (AU) 2020-12-23 EP claimed
US-20190290474-A1 DRUG RELEASE DEVICE AND USE JUROX PTY LTD (AU) 2019-09-26 US claimed
CN-109456381-A A kind of preparation method of Delmadinone 湖南科瑞生物制药股份有限公司 2019-03-12 CN claimed
CN-109456382-A A method of preparing delmadinone acetate 湖南科瑞生物制药股份有限公司 2019-03-12 CN claimed
CN-109369763-A A kind of preparation method of delmadinone acetate product 湖南科瑞生物制药股份有限公司 2019-02-22 CN claimed
CN-109369764-A A kind of preparation method of delmadinone acetate 湖南科瑞生物制药股份有限公司 2019-02-22 CN claimed
EP-3400050-A1 DRUG RELEASE DEVICE AND USE Jurox Pty. Ltd. (AU) 2018-11-14 EP claimed
WO-2017117627-A9 DRUG RELEASE DEVICE AND USE JUROX PTY LTD (AU) 2018-07-05 WO claimed
WO-2004058234-A2 PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2004-07-15 WO claimed
US-20040024230-A1 Synthesis of cyproterone acetate BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-02-05 US claimed
WO-2003092578-A2 FURTHER SYNTHESES OF CYPROTERONE ACETATE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2003-11-13 WO claimed
EP-1359154-A1 Further syntheses of cyproterone acetate BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) 2003-11-05 EP claimed
WO-2002057241-A1 8-(AMINOALKOXYMINO)-8H-DIBENZO[a,e]TRIAZOLO[4,5-c]CYCLOHEPTENES AS GROWTH HORMONE SECRETAGOGUES BAYER PHARMACEUTICALS CORPORATION (US) 2002-07-25 WO claimed
WO-2002056873-A2 2-SUBSTITUTED DIBENZO[A,E]1,2,3-TRIAZOLO[4,5-C][7]ANNULEN-8-ONES AS GROWTH HORMONE SECRETAGOGUES BAYER PHARMACEUTICALS CORPORATION (US) 2002-07-25 WO claimed
JP-2002522389-A 2002-07-23 JP claimed
EP-1102590-A1 USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING OR PREVENTING ABNORMAL BONE RESORPTION MERCK SHARP & DOHME LTD. (GB) 2001-05-30 EP claimed
US-6043026-A MIXTURE OF AN ESTROGEN RECEPTOR MODULATOR AND A GROWTH HORMONE SECRETAGOGUE MERCK & CO., INC. (US) 2000-03-28 US claimed
WO-2000007598-A1 USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING OR PREVENTING ABNORMAL BONE RESORPTION MERCK SHARP & DOHME LIMITED (GB) 2000-02-17 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024230-A1 Synthesis of cyproterone acetate CYP17A1, CYP19A1, CYP21A2 PGR 78/4885NR3C1 157/4885CYP3A4 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.